402 results on '"Imyanitov, E"'
Search Results
2. Founder vs. non-founder BRCA1/2 pathogenic alleles: the analysis of Belarusian breast and ovarian cancer patients and review of other studies on ethnically homogenous populations
3. HRD-negative high-grade carcinoma of the ovary in BRCA2 pathogenic variant carrier
4. CCND1 and FGFR1 gene amplifications are associated with reduced benefit from aromatase inhibitors in metastatic breast cancer
5. Predictive and prognostic features of early and locally advanced PIK3CA-mutated luminal HER2-negative breast cancer
6. Clinical impact of molecular genetic testing in pediatric oncology
7. BRCA-associated ovarian cancer in the russian patient population. Analysis of the non-interventional study Ovatar
8. BRCA1/2 mutation spectrum in Armenian patients with breast and ovarian cancers
9. Hereditary conditions associated with elevated cancer risk in childhood
10. Assessment of ERBB2 and HER2 expression in metastatic breast cancer using the nCounter® system and a 100-gene scale
11. Current approaches to systemic treatment of BRCA-associated triple-negative breast cancer
12. The efficacy of the TRK inhibitor entrectinib in patients with extracranial NTRK fusion-positive tumors
13. Hereditary predisposition to kidney cancer: cancer syndromes, multisystemic disorders, and nephropathies
14. Assessment of resection margins during breast-conserving surgery using multimodal optical coherence tomography
15. Consensus on the diagnosis and treatment of PROS (PIK3CA-related overgrowth spectrum). Russian version
16. Androgen receptor signaling mechanism in prostate cancer: resistance to antiandrogen therapy and association with DNA repair genes
17. THE CLINICAL OUTCOMES OF NEOADJUVANT THERAPY WITH CISPLATIN PLUS MITOMYCIN IN BRCA1-MUTATED OVARIAN CANCER: EP1010
18. NOVEL CLINICAL ROLES FOR BRCA1/2 GERM-LINE STATUS: 1) PRIMARY SURGERY IS SUPERIOR TO NEOADJUVANT CHEMOTHERAPY IN SPORADIC BUT NOT IN HEREDITARY OVARIAN CANCERS; 2) FAVORABLE ANATOMIC PATTERN OF RELAPSES IN BRCA1/2 MUTATION CARRIERS: EP875
19. MIR-190B-5P EXPRESSION IS A HIGHLY RELIABLE DISCRIMINATOR BETWEEN ER-POSITIVE AND ER-NEGATIVE BREAST CANCER: EP209
20. Immune checkpoint inhibitors for the treatment of solid tumors in HIV-infected patients: is it worth the risk?
21. Assessment of the effectiveness of surgical resections following tyrosine kinase inhibitor therapy in patients with EGFR-mutated stage III–IV lung adenocarcinoma
22. 52P The concentration of mutated copies of driver genes in plasma closely mirrors the disease course in colorectal cancer, lung cancer, and melanoma patients
23. 41P HLA genotypes modify the age-related penetrance of BRCA1 pathogenic variants in breast cancer patients
24. Reactivaion of immune-related colitis during targeted therapy in a patient with metastatic cutaneous melanoma
25. Hereditary ovarian cancer
26. Tumor immune microenvironment and apoptotic markers in breast cancer patients carrying BRCA1 gene mutations
27. Clinical and prognostic characteristics of BRCA1/2-associated breast cancer depending on the type of mutation: estrogen signaling pathway and secondary tumors
28. 356P Biallelic MUTYH germline inactivation in patients with colon polyposis and subjects with sporadic colorectal cancer
29. 1682P Development of an ex vivo RNA-based predictive assay for tumor tissue explants
30. 121P Spectrum of druggable gene fusions in microsatellite-unstable colorectal tumors
31. 25P Identification of novel kinase-activating fusions in non-small cell lung carcinomas (NSCLCs)
32. Adenomatous polyposis syndrome
33. Resolution on the results of Advisory Board “Searching the effective methods of testing and treating patients with NSCLC caused by NTRK gene fusions“
34. 40P Exome sequencing analysis of primary and recurrent ovarian carcinomas
35. 2P Spectrum of BRCA1, BRCA1, ATM and PALB2 alleles in ovarian cancer patients from North Caucasus
36. Founder vs. non-founder BRCA1/2 pathogenic alleles: the analysis of Belarusian breast and ovarian cancer patients and review of other studies on ethnically homogenous populations
37. A spectrum of overgrowth syndromes associated with the PIK3CA mutation. Literature review
38. 171P Detection of NTRK1/2/3 rearrangements by PCR test for 5’/3’-end unbalanced expression
39. Molecular genetic approaches to the prevention, diagnosis and treatment of neoplasms
40. Intratumor morphologic and molecular genetic heterogeneity in astrocytomas of different grade of malignancy in the material from the first operation
41. 176P Type of TP53 alteration may correlate with the extent of lymphocytic infiltration in high-grade serous ovarian carcinomas
42. Clinical and laboratory features of hereditary pheochromocytoma and paraganglioma
43. 175 Cost-efficient analysis of BRCAness status in high-grade serous ovarian carcinomas
44. 174 Analysis of consecutive high-grade serous ovarian cancer patients allows efficient cataloging of BRCA1/2 mutations in yet unstudied ethnic groups
45. CHANGES IN THE MGMT GENE EXPRESSION IN PATIENTS WITH PRIMARY GLIOBLASTOMA AFTER RELAPSE. INFLUENCE OF CLINICAL CHARACTERISTICS AND MGMT EXPRESSION ON SURVIVAL OF PATIENTS
46. Age-related and clinicopathological features of colorectal cancer associated with K-ras gene status
47. 2263P Ethnicity-specific distribution of BRCA1, BRCA2, PALB2 and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus
48. 211P Cost-efficient detection of NTRK1, NTRK2 and NTRK3 gene rearrangements using the test for 5’/3’-end unbalanced expression: The analysis of 8075 patients
49. Polymorphic markers associated with genes responsible for lipid and carbohydrate metabolism disorders and insulin resistance in cancer patients
50. Molecular diagnosis in oncology
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.